Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 02-14 15:00:00

45.50

+0.86

+1.93%

High45.77	Low44.56	Vol52.22M
Open44.62	D1 Closing44.64	Amplitude2.71%
Mkt Cap290.24B	Tradable Cap290.24B	Total Shares6.38B
T/O2.36B	T/O Rate0.82%	Tradable Shares6.38B
P/B6.63	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":45.5,"timestamp":1739516400000,"preClose":44.64,"halted":0,"volume":52217434,"delay":0,"changeRate":0.0193,"floatShares":6379000000,"shares":6379000000,"eps":0.8541,"marketStatus":"Closed","change":0.86,"latestTime":"02-14 15:00:00","open":44.62,"high":45.77,"low":44.56,"amount":2363000000,"amplitude":0.0271,"askPrice":45.5,"askSize":347,"bidPrice":45.49,"bidSize":815,"shortable":0,"etf":0,"ttmEps":0.8541,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1739755800000},"marketStatusCode":5,"adr":0,"adjPreClose":44.64,"symbolType":"stock","openAndCloseTimeList":[[1739496600000,1739503800000],[1739509200000,1739516400000]],"highLimit":49.1,"lowLimit":40.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"isCdr":false,"pbRate":6.63,"roa":"--","peRate":53.272451,"roe":"10.88%","epsLYR":0.68,"committee":0.215195,"marketValue":290245000000,"turnoverRate":0.0082,"status":0,"floatMarketCap":290245000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2511686052","title":"Hengrui Medicine Gets Approval for Spondyloarthritis Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2511686052","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511686052?lang=en_us&edition=fundamental","pubTime":"2025-02-14 10:24","pubTimestamp":1739499874,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) obtained approval from China's drug administrator to conduct clinical trials of funaqizumab injection for radiologically negative axial spondyloarthritis, according to a Thursday filing with the Shanghai bourse.Shares of the company rose 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2505393928","title":"Jiangsu Hengrui Medicine Applies for Drug Marketing Authorization for Insulin Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2505393928","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505393928?lang=en_us&edition=fundamental","pubTime":"2025-01-24 17:28","pubTimestamp":1737710888,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  said China's drug administrator received its drug marketing authorization application for Shudi insulin injection.The injection is indicated for treating type two diabetes in adults, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company closed 2% higher Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2504907388","title":"Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for Two Anti-tumor Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2504907388","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504907388?lang=en_us&edition=fundamental","pubTime":"2025-01-17 13:34","pubTimestamp":1737092047,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  subsidiaries Suzhou Shengdia Biopharmaceutical and Shanghai Hengrui Medicine obtained the approval of China's medical products administrator to conduct clinical trials for two anti-tumor drugs.SHR-A1811 induces tumor cell apoptosis and SHR-9839 is intended to treat advanced malignant tumors, according to a Thursday filing with the Shanghai bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2503650926","title":"Jiangsu Hengrui Medicine Gets China Clinical Trial Approval for Anti-Tumor Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650926?lang=en_us&edition=fundamental","pubTime":"2025-01-15 12:33","pubTimestamp":1736915634,"startTime":"0","endTime":"0","summary":"Chinese authorities approved the clinical trial of Jiangsu Hengrui Medicine  units Shanghai Hengrui Medicine and Suzhou Shengdia Biopharmaceutical for the SHR-9839 injection for malignant tumors, according to a Wednesday filing with the Shanghai Stock Exchange.The drug is an antibody that simultaneously blocks two signal pathways related to tumor occurrence and development, the filing said.Shares fell 1% during Wednesday's late morning trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2503665831","title":"Chinese Shares Open Lower; Property, Pharma Stocks Weigh -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2503665831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503665831?lang=en_us&edition=fundamental","pubTime":"2025-01-15 09:52","pubTimestamp":1736905920,"startTime":"0","endTime":"0","summary":"0152 GMT - Chinese shares open lower after a rally in the previous session. Real estate and pharmaceutical stocks lead the losses. Investors are awaiting China's 4Q economic data later this week and Donald Trump's inauguration next week. China Vanke declines 1.45% and Poly Developments & Holdings is down 1.25%. Jiangsu Hengrui Medicine drops 1.3% and WuXi AppTec falls 2.2%. Bank stocks are broadly higher, with Industrial & Commercial Bank of China up 1.4% and Agricultural Bank of China gaining 1.6%. The benchmark Shanghai Composite Index drops 0.2% to 3235.47, the Shenzhen Composite Index is 0.7% lower and the ChiNext Price Index sheds 1.5%. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603259","LU2039709279.SGD","SG9999001051.SGD","BK0060","01288","LU1522347837.USD","LU1880383366.USD","LU1969619763.USD","03143","601288","LU1064131003.USD","LU1224709979.USD","CFA.SI","LU1497734951.SGD","BK0278","600276","LU1813983027.USD","BK0183","IE00BVYPNP33.GBP","BK0082","BK0189","IDCBY","LU1497733557.USD","LU0405327494.USD","LU1794554557.SGD","IE00BYV24P56.USD","BK0015","IE00BGHQDM52.EUR","LU0456842615.SGD","IE0032431581.USD","LU2495084118.USD","SGXZ90724238.SGD","LU1997245094.SGD","601398","LU1997245177.USD","LU1997244956.HKD","LU0823426308.USD","ACGBY","LU1720050803.USD","BK1521","LU2328871848.SGD","600048","BK4207","LU2488822045.USD","LU2148510915.USD","LU0359201885.HKD","BK0188","01398","BK0196","LU1064130708.USD"],"gpt_icon":0},{"id":"2503342605","title":"Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials on Anti-Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503342605","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503342605?lang=en_us&edition=fundamental","pubTime":"2025-01-13 13:26","pubTimestamp":1736745997,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) secured approval from China's medical products administrator to conduct clinical trials for its SHR-4375 injection.The drug is intended to treat advanced malignant solid tumors, according to a Jan. 10 filing with the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2503345245","title":"Jiangsu Hengrui Medicine Gets Drug Registration for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503345245","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503345245?lang=en_us&edition=fundamental","pubTime":"2025-01-13 11:39","pubTimestamp":1736739595,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) obtained a drug registration for its recalcitrol injection from China's drug administrator.Recalcitrol is indicated for primary hypercholesterolemia and mixed dys","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","CSII","600276"],"gpt_icon":0},{"id":"2502000958","title":"Chinese Drug Regulator Accepts Hengrui Medicine's Marketing Application for SHR4640 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2502000958","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502000958?lang=en_us&edition=fundamental","pubTime":"2025-01-10 12:31","pubTimestamp":1736483479,"startTime":"0","endTime":"0","summary":"The Chinese drug administration accepted Jiangsu Hengrui Medicine's  marketing application for SHR4640 tablets, according to a Shanghai Stock Exchange disclosure on Thursday.The pharmaceutical company invested 279.9 million yuan into the drug, which is suitable for long-term treatment of primary gout with hyperuricemia, the disclosure said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2501571121","title":"Chinese Shares Close Mixed Amid Weak Yuan; Mabwell (Shanghai) Bioscience Down 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501571121","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501571121?lang=en_us&edition=fundamental","pubTime":"2025-01-08 15:51","pubTimestamp":1736322662,"startTime":"0","endTime":"0","summary":"Chinese stocks traded mainly in the red throughout the day before closing mixed on Wednesday as the continued weakness of the yuan dampened appetite for riskier assets.The Shanghai Composite Index, the main gauge of Chinese stocks, ended the day's session marginally higher at 3,230.17 after logging losses in earlier trade. The Shenzhen Component Index, however, declined 0.5% to 9,944.64.China's currency fell to its lowest in 16 months on Wednesday despite the People's Bank of China's efforts of setting stronger-than-expected guidance, Reuters reported.\"The yuan is expected to face depreciation pressure, not only from tariff hikes but also from a significantly stronger dollar,\" Reuters cited Wang Tao, chief China economist at UBS, as saying.Two Shanghai-listed companies, Jiangsu Hengrui Medicine  and Mabwell  Bioscience , filed for listing on the Hong Kong bourse. Shares of Jiangsu Hengrui Medicine closed 1% lower, while shares of Mabwell  Bioscience were down 2%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276","BK0196","LU2328871848.SGD","688062","LU1064130708.USD","LU2488822045.USD","LU0405327148.USD","BK0239","LU1969619763.USD","LU1328615791.USD","BK0012","LU1064131003.USD","LU0405327494.USD","LU2148510915.USD","BK0060","BK0028","BK0188","BK0183"],"gpt_icon":0},{"id":"2501793924","title":"Jiangsu Hengrui Medicine Files for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501793924","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501793924?lang=en_us&edition=fundamental","pubTime":"2025-01-08 11:39","pubTimestamp":1736307544,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  on Jan. 6 filed to list its shares on the Hong Kong bourse, according to a filing with the Shanghai bourse.Morgan Stanley, Citigroup Inc. and Huatai Securities Co. are arranging the deal, according to a Hong Kong bourse filing.The share sale could fetch at least $2 billion, Bloomberg News reported Tuesday, citing people familiar with the matter.Shares of the pharmaceutical company were down 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0060","LU0912757837.SGD","LU1989772840.SGD","600276","BK4588","LU1328615791.USD","LU1732800096.USD","BK4585","LU1969619763.USD","LU0225283273.USD","LU2111349929.HKD","LU2028103732.USD","BK4516","LU2089283258.USD","BK0028","LU0106261372.USD","LU2148510915.USD","LU1668664300.SGD","LU0314104364.USD","LU0405327148.USD","LU0971096721.USD","BK0183","LU2488822045.USD","LU2357305700.SGD","LU2023251221.USD","LU0795875169.SGD","LU2347655156.SGD","LU0267386448.USD","LU0158827781.USD","LU0106831901.USD","BK0012","BK4127","LU0405327494.USD","LU0795875086.SGD","LU1074936037.SGD","LU1548497426.USD","LU1732799900.SGD","LU2271345857.HKD","BK4504","LU1064131003.USD","LU1162221912.USD","LU0320765646.SGD","BK0239","LU0098860793.USD","BK4581","LU1064130708.USD","LU2089284900.SGD","BK4534","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2501292221","title":"China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2501292221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501292221?lang=en_us&edition=fundamental","pubTime":"2025-01-07 16:23","pubTimestamp":1736238180,"startTime":"0","endTime":"0","summary":"0822 GMT - China's healthcare sector will likely get a significant boost from national policies in 1Q, Citi analysts write in a note. This year marks the start of the most positive structural change in the industry, as it will be the first time that China's public healthcare system is able to include commercial insurance providers as significant payers, they say. The brokerage recommends buying shares in companies that will be direct beneficiaries of the reform. These include pharmaceutical and biopharmaceutical firms, pharmaceutical distributors and medical device companies. Citi's top picks include Jiangsu Hengrui Medicine, Hansoh Pharmaceutical, SSY Group, Akeso, Sichuan Kelun-Biotech Biopharmaceutical, Mindray Medical, Sinopharm Group, WuXi AppTec, Wuxi Biologics and Gushengtang. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU0348825331.USD","06990","LU0405327148.USD","BK1576","LU0052750758.USD","LU0516422366.SGD","LU0039217434.USD","LU0516422952.EUR","HCSG","BK1574","BK0196","LU0359202008.SGD","BK4137","LU0516422440.USD","SHTDY","BK1610","02005","02269","BK0012","LU1328615791.USD","LU0979878070.USD","LU1997245094.SGD","IE00B543WZ88.USD","603259","03692","LU2460026573.USD","01099","LU0348735423.USD","LU1064131003.USD","LU0516423174.USD","LU0588546209.SGD","LU1242518857.USD","BK1191","LU0348784397.USD","LU0856984785.SGD","LU1880383366.USD","LU0456846285.SGD","LU0359201612.USD","LU0640798160.USD","BK1219","09926","LU0196878994.USD","BK1589","BK1583","LU0326950275.SGD","02273","LU0819121731.USD","600276","BK0188"],"gpt_icon":0},{"id":"2501256533","title":"Hengrui Pharmaceuticals Submits Application For Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501256533","media":"T-Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501256533?lang=en_us&edition=fundamental","pubTime":"2025-01-06 23:10","pubTimestamp":1736176254,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co Ltd <600276.SS>:Says Application For H-Share Issuance And Listing Submitted To Hong Kong Stock Exchange.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0012","LU0405327148.USD","LU1064130708.USD","LU1328615791.USD","BK0239","LU2488822045.USD","LU2328871848.SGD","LU2148510915.USD","BK0196","BK0028","LU1969619763.USD","LU0405327494.USD","BK0183","600276","BK0188","LU1064131003.USD"],"gpt_icon":0},{"id":"2501255698","title":"Hengrui Pharmaceuticals  Says Application for H-Share Issuance and Listing Submitted to Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2501255698","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501255698?lang=en_us&edition=fundamental","pubTime":"2025-01-06 23:10","pubTimestamp":1736176254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nL4N3O2131:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","LU2488822045.USD","600276","BK0188","LU0405327494.USD","LU2328871848.SGD","BK0060","LU1064131003.USD","LU1328615791.USD","BK0012","BK0239","BK0183","LU1064130708.USD","LU1969619763.USD","LU0405327148.USD","LU2148510915.USD","BK0196"],"gpt_icon":0},{"id":"2501403938","title":"Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for HRS-6768 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2501403938","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501403938?lang=en_us&edition=fundamental","pubTime":"2025-01-06 14:50","pubTimestamp":1736146242,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  received approval from China's drug administrator to conduct clinical trials for the HRS-6768 injection.HRS-6768 is suitable for patients with advanced solid tumors who are positive for fibroblast activation protein, according to a Jan. 3 filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2495970135","title":"Jiangsu Hengrui's Early-Stage Assets Poised to Unlock Upside Potential -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2495970135","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495970135?lang=en_us&edition=fundamental","pubTime":"2024-12-30 16:33","pubTimestamp":1735547580,"startTime":"0","endTime":"0","summary":"0833 GMT - Jiangsu Hengrui's early-stage assets may offer upside potential for the stock, Citi analysts write in a note. The company will receive a $75 million upfront payment and up to $200 million in development and regulatory milestone payments after securing a license-out agreement for global rights to one of its tumor drugs. Initial clinical data from the drug's Phase 1 trials in China have shown encouraging results, the analysts say. Citi anticipates more business development collaborations, focusing on earlier-stage projects, including preclinical assets, in 2024. The analysts believe the valuation of Hengrui's early-stage assets has not been fully factored in by investors and could present additional upside potential. Citi maintains a buy rating on the stock with a target price of CNY123.00. Shares last closed at CNY46.14. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1328615791.USD","BK0239","BK0196","SSI","LU2488822045.USD","BK0028","600276","LU1064131003.USD","LU1064130708.USD","LU0405327148.USD","LU0405327494.USD","BK0060","BK0012","BK0188","BK0183"],"gpt_icon":0},{"id":"2495309977","title":"Hengrui Pharmaceuticals  Says Co Signs Shr-4849 Project License Agreement With IDEAYA Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2495309977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495309977?lang=en_us&edition=fundamental","pubTime":"2024-12-29 16:49","pubTimestamp":1735462150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241229:nL4N3NU046:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600276","BK0196","LU1064130708.USD","IDYA","LU2488822045.USD","LU2148510915.USD","BK0028","BK0183","BK0188","BK0239","BK4139","LU0405327148.USD","LU1064131003.USD","LU0405327494.USD","BK0060","BK0012","LU1328615791.USD"],"gpt_icon":0},{"id":"2495030927","title":"BRIEF-Hengrui Pharmaceuticals Signs SHR-4849 Project License Agreement With Ideaya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2495030927","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495030927?lang=en_us&edition=fundamental","pubTime":"2024-12-29 16:49","pubTimestamp":1735462150,"startTime":"0","endTime":"0","summary":"BRIEF-Hengrui Pharmaceuticals Signs SHR-4849 Project License Agreement With Ideaya BiosciencesDec 29  - Jiangsu Hengrui Pharmaceuticals Co Ltd 600276.SS:SAYS CO SIGNS EARNINGS PER SHARE-4849 PROJECT LICENSE AGREEMENT WITH IDEAYA BIOSCIENCESSource textFurther company coverage: 600276.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241229:nL4N3NU046:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","IDYA","LU2488822045.USD","LU1328615791.USD","BK0188","LU0405327148.USD","BK0012","BK0196","BK0239","600276","LU1064130708.USD","BK0028","BK4139","LU1064131003.USD","LU0405327494.USD","LU2148510915.USD","BK0183"],"gpt_icon":0},{"id":"2494886567","title":"Hengrui Medicine Gets Nod to Trial Prostate Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2494886567","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494886567?lang=en_us&edition=fundamental","pubTime":"2024-12-26 11:56","pubTimestamp":1735185373,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  will conduct clinical trials on the HRS-4357 injection after receiving approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Wednesday.The drug will be tested in combination with ADT and new androgen receptor pathway inhibitors as a treatment for prostate cancer.The Chinese drugmaker invested 48.1 million yuan in the research and development of the drug, the disclosure added.Hengrui's shares slipped 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","LU0405327148.USD","LU2488822045.USD","BK0028","BK0239","BK0012","BK0188","LU1064130708.USD","LU1328615791.USD","BK0196","600276","LU2148510915.USD","BK0183","LU0405327494.USD","BK0060"],"gpt_icon":0},{"id":"2493201120","title":"Hengrui Medicine Subsidiaries Receive Approval for Anti-Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2493201120","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493201120?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:58","pubTimestamp":1734926306,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  units Shanghai Shengdi Pharmaceutical and Suzhou Shengdia Biopharmaceutical obtained Chinese drug trial approval for SHR-1681 for injection, according to a Saturday filing with the Shanghai Stock Exchange.The drug is indicated for anti-tumor activity, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2492117111","title":"Jiangsu Hengrui Medicine Gets China Green Light for Bladder Cancer Drug Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492117111","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492117111?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593405,"startTime":"0","endTime":"0","summary":"China approved the clinical trial of Jiangsu Hengrui Medicine  units Shanghai Hengrui Medicine and Shanghai Shengdi Pharmaceutical for the SHR-1501 and adebelimumab injections, according to a Thursday filing with the Shanghai Stock Exchange.The combination of SHR-1501 and adebelimumab are indicated for clinical trials for non-muscle-invasive bladder cancer, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0369},{"period":"3month","weight":-0.0461},{"period":"6month","weight":0.0552},{"period":"1year","weight":0.0921},{"period":"ytd","weight":-0.0087}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"15265股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0371},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1623},{"period":"1year","weight":0.1678},{"period":"ytd","weight":-0.0015}],"survey":"　　江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售，主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内，公司严格遵守环境保护法，依法持证排污，并按时缴纳环境保护税，环保信用评价等级为“绿色”，为“环保示范性企事业单位”及江苏省“绿色发展领军企业”，获得连云港经济技术开发区企业“环境保护质量奖”荣誉。","serverTime":1739750575583,"listedPrice":11.98,"stockholders":"417865人(较上一季度减少8.23%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction